{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:39:17Z","timestamp":1787071157428,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rituximab infusion and dexamethasone-cyclophosphamide pulse (DCP) are the two most popular regimens used in pemphigus vulgaris (PV) in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The present study compared the clinical efficacy of rituximab and DCP in Indian PV patients and their effects on serum Th1,2, and 17 cytokine levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 37 patients received DCP (Group A,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 22) or rituximab (Group B, rheumatoid arthritis protocol (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 15)) as per patients\u2019 preference. They were monitored for clinical response, adverse events (AEs), changes in serum anti-desmoglein-1,3 antibody titers and Th1,2 and 17 cytokine levels at baseline and weeks 20 and 52.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The proportion of patients attaining disease control, remission, and relapse in groups A and B were 82% and 93%; 73% and 93%; and 27% and 50%, respectively, after a median duration of 2 months each for disease control; 4 and 4.5 months for remission; and 5 and 7 months for relapse post remission. The musculoskeletal AEs were the highest in the two groups. Significant and comparable decreases in anti-dsg1 and 3 titers from baseline to weeks 20 and 52 were observed in both groups. Th1 and Th17 cytokine levels decreased, while Th2 cytokines increased post-treatment in both groups. However, no correlation was found between change in body surface area of involvement by PV and anti-dsg titers and cytokine levels before and after therapy in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Comparable clinical efficacy between DCP and rituximab was observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_558_23","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:19:49Z","timestamp":1714393189000},"page":"464-472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the Clinical Efficacy of Rituximab Infusion and Dexamethasone-Cyclophosphamide Pulse Therapy and Their Effect on Serum Th1, Th2, and Th17 Cytokines in Pemphigus Vulgaris\u2013A Prospective, Nonrandomized, Comparative Pilot Study"],"prefix":"10.4103","volume":"15","author":[{"given":"Sujay","family":"Khandpur","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod K.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Sharda University, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayasagar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Bhari","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnubhatla","family":"Sreenivas","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, AIIMS, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/jid.2011.249","article-title":"Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: A nationwide population-based study","volume":"132","author":"Huang","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R2-20250921","first-page":"199","article-title":"Pulse therapy with dexamethasone-cyclophosphamide in pemphigus","volume":"50","author":"Pasricha","year":"1984","journal-title":"Indian J DermatolVenereolLeprol"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fmed.2018.00218","article-title":"The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the \u201cSuper Compensation Hypothesis\u201d","volume":"5","author":"Sinha","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R5-20250921","doi-asserted-by":"crossref","first-page":"e0198074","DOI":"10.1371\/journal.pone.0198074","article-title":"Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis","volume":"13","author":"Agarwal","year":"2018","journal-title":"PLoS One"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritu\u00d73): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000057886","article-title":"Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus","volume":"204","author":"Kanwar","year":"2002","journal-title":"Dermatology"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/0378-6323.55390","article-title":"Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris","volume":"75","author":"Sethy","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R12-20250921","first-page":"WC01","article-title":"Rituximab: A Magic Bullet for Pemphigus","volume":"11","author":"Anandan","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"R13-20250921","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R14-20250921","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/11311150-000000000-00000","article-title":"Dexamethasone-cyclophosphamide pulse therapy in pemphigus: A review of 72 cases","volume":"11","author":"Zivanovic","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R15-20250921","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2230.2009.03450.x","article-title":"Corticosteroid\/cyclophosphamide pulse treatment in South African patients with pemphigus","volume":"35","author":"Shaik","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"R16-20250921","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250921","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R18-20250921","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/ijdvl.IJDVL_175_17","article-title":"A review of pulse therapy in 74 patients with pemphigus","volume":"84","author":"Roga","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R19-20250921","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20250921","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250921","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/CDR.CDR_42_17","article-title":"Outcome of pulse therapy in pemphigus: A 10-year study","volume":"2","author":"Varala","year":"2018","journal-title":"Clin Dermatol Rev"},{"key":"R22-20250921","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R24-20250921","first-page":"354","article-title":"Dexamethasone-Cyclophosphamide pulse (DCP) therapy in Pemphigus","volume":"63","author":"Roy","year":"1997","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R25-20250921","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard.58.1.49","article-title":"The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production","volume":"58","author":"Verhoef","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"R26-20250921","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.3389\/fimmu.2019.02992","article-title":"Effects of methotrexate alone or combined with arthritis-related biotherapies in an in vitro co-culture model with immune cells and synoviocytes","volume":"10","author":"Noack","year":"2019","journal-title":"Front Immunol"},{"key":"R27-20250921","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.175.3.637","article-title":"Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements","volume":"175","author":"Vacca","year":"1992","journal-title":"J Exp Med"},{"key":"R28-20250921","first-page":"31","article-title":"Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis","volume":"6","author":"Hasan","year":"2012","journal-title":"Biologics"},{"key":"R29-20250921","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1871530319666190215153213","article-title":"Rituximab treatment modulates the release of hydrogen peroxide and the production of proinflammatory cytokines by monocyte at the onset of Type 1 diabetes","volume":"19","author":"Hamouda","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R30-20250921","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.30314","article-title":"The anti-CD20 antibody rituximab reduces the Th17 cell response","volume":"63","author":"van de Veerdonk","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_558_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:21Z","timestamp":1787067741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_558_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_558_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"2023-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}